1st Oct 2018 07:56
LONDON (Alliance News) - AstraZeneca PLC on Monday said it agreed to sell commercial rights for Atacand and Atacand Plus in Europe to Cheplapharm Arzneimittel GmbH.
Atacand is a receptor antagonist blocker for the treatment of hypertension and heart failure.
Under the terms of the agreement, the FTSE 100-listed pharmaceutical company said it has received a payment of USD200 million from Cheplapharm. In addition to that, AstraZeneca said it will secure a time-bound payment of USD10 million as well as sales-contingent milestones.
AstraZeneca said it will continue to manufacture and supply Atacand and Atacand Plus under the agreement and will continue to commercialise the medicines in all markets where it still holds the rights.
Related Shares:
Astrazeneca